Patricia M LoRusso (Patricia LoRusso, Patricia Lorusso)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 38

Top Topics

Epidermal Growth Factor Receptor

Top Venues

Cancer research communications

Nature medicine

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Evanthia T Roussos Torres, Won Jin Ho, Ludmila Danilova, Joseph A Tandurella, James Leatherman, Christine Rafie, Chenguang Wang, Adam M Brufsky, Patricia M LoRusso, Vincent Chung, Yuan Yuan, Melinda Downs, Ashley O'Connor, Sarah M Shin, Alexei Hernandez, Elizabeth L Engle, Richard Piekarz, Howard Streicher, Zahra Talebi, Michelle A Rudek, Qingfeng Zhu, Robert A Anders, Ashley Cimino-Mathews, Elana J Fertig, Elizabeth D Thompson, Vered Stearns, Caitriona Cahir
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nature cancer 5 (6) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine 30 (8) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Evanthia T Roussos Torres, Won Jin Ho, Ludmila Danilova, Joseph A Tandurella, James Leatherman, Christine Rafie, Chenguang Wang, Adam M Brufsky, Patricia M LoRusso, Vincent Chung, Yuan Yuan, Melinda Downs, Ashley O'Connor, Sarah M Shin, Alexei Hernandez, Elizabeth L Engle, Richard Piekarz, Howard Streicher, Zahra Talebi, Michelle A Rudek, Qingfeng Zhu, Robert A Anders, Ashley Cimino-Mathews, Elana J Fertig, Elizabeth D Thompson, Vered Stearns, Caitriona Cahir
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nature cancer 5 (6) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Evanthia T Roussos Torres, Won Jin Ho, Ludmila Danilova, Joseph A Tandurella, James Leatherman, Christine Rafie, Chenguang Wang, Adam M Brufsky, Patricia M LoRusso, Vincent Chung, Yuan Yuan, Melinda Downs, Ashley O'Connor, Sarah M Shin, Alexei Hernandez, Elizabeth L Engle, Richard Piekarz, Howard Streicher, Zahra Talebi, Michelle A Rudek, Qingfeng Zhu, Robert A Anders, Ashley Cimino-Mathews, Elana J Fertig, Elizabeth D Thompson, Vered Stearns, Caitriona Cahir
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nature cancer 5 (6) (2024)
Yoonha Choi, Neekesh V Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K Yau, Zoe June Assaf, Junko Aimi, Smruthy S Sivakumar, Meagan Montesion, Adrian Sacher, Patricia M LoRusso, Jayesh Desai, Jennifer L Schutzman, Zhen Shi
Circulating tumor DNA dynamics reveal KRAS G12C mutation heterogeneity and response to treatment with the KRAS G12C inhibitor divarasib in solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Yoonha Choi, Neekesh V Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K Yau, Zoe June Assaf, Junko Aimi, Smruthy S Sivakumar, Meagan Montesion, Adrian Sacher, Patricia M LoRusso, Jayesh Desai, Jennifer L Schutzman, Zhen Shi, null null
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (17) (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine 30 (8) (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine 30 (8) (2024)
Evanthia T Roussos Torres, Won Jin Ho, Ludmila Danilova, Joseph A Tandurella, James Leatherman, Christine Rafie, Chenguang Wang, Adam M Brufsky, Patricia M LoRusso, Vincent Chung, Yuan Yuan, Melinda Downs, Ashley O'Connor, Sarah M Shin, Alexei Hernandez, Elizabeth L Engle, Richard Piekarz, Howard Streicher, Zahra Talebi, Michelle A Rudek, Qingfeng Zhu, Robert A Anders, Ashley Cimino-Mathews, Elana J Fertig, Elizabeth D Thompson, Vered Stearns, Caitriona Cahir
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nature cancer (2024)
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Paige Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial. Nature medicine (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Genee Lee, Donglu Zhang, Peter S Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas D Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M Violet Lee, Ola M Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Paige Hamilton, Patricia M LoRusso, Ian Krop, Melissa M Schutten, Renee Commerford, Mark X Sliwkowski, Eunpi Cho
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications 15 (1) (2024)
Kristina A Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A Boerner, Jing Li, Diane E Durecki, Jan Drappatz, Vinay K Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, Susan Percy Ivy, Ranjit S Bindra, Antonio Omuro, Patricia M LoRusso
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer research communications 3 (2) (2023)
Kristina A Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A Boerner, Jing Li, Diane E Durecki, Jan Drappatz, Vinay K Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, Susan Percy Ivy, Ranjit S Bindra, Antonio Omuro, Patricia M LoRusso
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer research communications 3 (2) (2023)
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey S Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kortmansky, Kimberly L Johung, Ranjit S Bindra, Patricia M LoRusso, Kurt A Schalper
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Patricia M LoRusso, Noboru Yamamoto, Manish R Patel, Scott A Laurie, Todd M Bauer, Junxian Geng, Teffany Davenport, Michael Teufel, Jian Li, Mehdi Lahmar, Mrinal M Gounder
The MDM2-p53 antagonist BI 907828 in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study. Cancer discovery (2023)
Jayesh Desai, Guzman Alonso, Se Hyun Kim, Andres Cervantes, Thomas Benjamin Karasic, Laura Medina, Einat Shacham-Shmueli, Rasha Cosman, Alejandro Falcón Gonzalez, Eelke Gort, Tormod Kyrre Guren, Erminia Massarelli, Wilson H Miller, Luis Paz-Ares, Hans Prenen, Alessio Amatu, Chiara Cremolini, Tae Won Kim, Victor Moreno, Sai-Hong Ignatius Ou, Alessandro Passardi, Adrian Sacher, Armando Santoro, Rafal Stec, Susanna Ulahannan, Kathryn C Arbour, Patricia M LoRusso, Jia Luo, Manish R Patel, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T Lin, Stephanie Royer-Joo, Julie Chang, Tomi Jun, Neekesh V Dharia, Jennifer L Schutzman, null null, Sae-Won Han
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nature medicine (2023)
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey S Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kortmansky, Kimberly L Johung, Ranjit S Bindra, Patricia M LoRusso, Kurt A Schalper
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey S Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kortmansky, Kimberly L Johung, Ranjit S Bindra, Patricia M LoRusso, Kurt A Schalper
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael A Carducci, Ding Wang, Christina Habermehl, Matthias Bödding, Felix Rohdich, Floriane Lignet, Klaus Duecker, Oleksandr Karpenko, Linda Pudelko, Claude Gimmi, Patricia M LoRusso
A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors. Cancer research communications 3 (8) (2023)
Timothy Anthony Yap, Patricia M LoRusso, Deborah J Wong, Siwen Hu-Lieskovan, Kyriakos P Papadopoulos, Josefin-Beate Holz, Urszula Grabowska, Cristian Gradinaru, Kin-Mei Leung, Sylwia Marshall, Claire S Reader, Roslin Russell, Richard C A Sainson, Claire J Seal, Christopher J Shepherd, Fiona Germaschewski, Daniel R Gliddon, Omer Stern, Lesley Young, Neil Brewis, Louis Kayitalire, Michelle Morrow
A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)